1. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. http://nlep.nic.in/pdf/WHO%20Guidelines%20for%20leprosy.pdf Retrieved on 10/01/2019.
2. Pharmacovigilance. https: //www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Accessed on 11/01/2019.
3. Thangaraju P, Venkatesan S, Tamilselvan T, Sivashanmugam E, Showkath Ali M K. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring among medical professionals attending Central Leprosy Institute. Mustansiriya Med J 2018;17:63-8
DSÖ lepra tedavi kılavuzu: farmakovijilansa odaklanma
1. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy. http://nlep.nic.in/pdf/WHO%20Guidelines%20for%20leprosy.pdf Retrieved on 10/01/2019.
2. Pharmacovigilance. https: //www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. Accessed on 11/01/2019.
3. Thangaraju P, Venkatesan S, Tamilselvan T, Sivashanmugam E, Showkath Ali M K. Evaluation of awareness about pharmacovigilance and adverse drug reaction monitoring among medical professionals attending Central Leprosy Institute. Mustansiriya Med J 2018;17:63-8
Thangaraju, Pugazhenthan and Sajitha Venkatesan. “WHO Treatment Guidelines Against Leprosy: A Focus on Pharmacovigilance”. Cukurova Medical Journal, vol. 44, no. 2, 2019, pp. 701-2, doi:10.17826/cumj.511810.